Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Phase II clinical trial commences for Merck & Co./Arena niacin receptor agonist

Feb. 19, 2009

GSK initiates phase III program for novel type 2 diabetes drug, Syncria

Feb. 18, 2009

Shionogi presents positive top-line efficacy results from velneperit studies

Feb. 17, 2009

Diamyd receives approval for follow-up study for its diabetes vaccine

Feb. 17, 2009

New histamine H3 receptor ligands reported in recent High Point patent

Feb. 17, 2009

Teijin and Takeda receive FDA approval for febuxostat for hyperuricemia in gout

Feb. 16, 2009

Savient updates pegloticase BLA

Feb. 13, 2009

Palatin receives payments from AstraZeneca related to melanocortin receptor collaboration

Feb. 13, 2009

Breast cancer risk declines following discontinuation of estrogen plus progestin therapy

Feb. 13, 2009

Genaera presents preliminary phase Ib trodusquemine results

Feb. 13, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...